Abstract

Primary liver cancer is the most common tumor in China, with high morbidity and mortality. Nanotechnology has made continuous progress in recent years. In this study, new liposome nanoparticles were used to assemble the bone marrow mesenchymal stem cell (BMSC)-liposome nano-drug delivery system, to explore molecular mechanism of this technology in anti-HBV-related liver cancer. In this study, human hepatitis Brelated liver cancer cells were exposed to the novel BMSC-liposome nano-drug delivery system, and specific methylation analysis PCR (MSP) was used to detect cell apoptosis. Flow cytometry analysis was used to test cell cycle. Proliferation of human hepatitis B-related liver cancer cell line HepG2 was analyzed by MTT, while DNA methyltransferase (DNMT)/hepatitis B virus X protein (HBx) methylation status was detected by real time PCR. The new liposomal nanoparticle BMSC nano-drug delivery system increased the rate of cell apoptosis, inhibited the proliferation of HepG2, and blocked the cells in the G2/M phase. In addition, the new liposomal nanoparticle BMSC nano-drug delivery system reduced the content of hepatitis B virus X protein (HBx) in the HepG2 cells, and regulated virus replication by controlling the expression of methyltransferase (DNMT). DNA methylation level is one of the criteria for evaluating virus replication. The results from this study suggest that low-level methylation can contribute to the occurrence and development of tumors, and regional CpG island hypermethylation can increase DNase, to effectively promote the development of viral related diseases. HBx can effectively promote the progress of liver cancer through the expression of DNMT. In this study, a novel BMSC-liposome drug delivery system effectively controlled the replication of hepatitis B virus and increased the apoptosis of liver cancer cells. This process is closely related to inhibition of DNA methylase and promotion of HBx methylation.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.